Cart
sales@molnova.com
Retatrutide
CAS No. 2381089-83-2
Retatrutide( —— )
Catalog No. M36652 CAS No. 2381089-83-2
Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 591 | In Stock |
|
| 10MG | 947 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRetatrutide
-
NoteResearch use only, not for human use.
-
Brief DescriptionRetatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
-
DescriptionRetatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
-
In Vitro——
-
In VivoAnimal Model:Diet-induced obese (DIO) male C57/Bl6 mice (24-25 weeks, 40-51 g) Dosage:10 mL/kg Administration:Subcutaneous (SC) injection, cycle every 3 days, for 21 days Result:Decreased body weight and improved glycemic control.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2381089-83-2
-
Formula Weight4731.33
-
Molecular FormulaC221H342N46O68
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (10.57 mM; Ultrasonic ) H2O : 33.33 mg/mL (7.04 mM; ultrasonic and adjust pH to 7 with NaOH)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.?
molnova catalog
related products
-
Bay 55-9837
Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1 agonists.
-
HAEGT
HAEGT is the first N-terminal 1-5 residues of GLP-1 peptide.
-
Exenatide acetate
Exenatide acetate (Exendin-4 acetate) is the acetate of Exenatide, which is highly potent, long-acting glucagon-like peptide-1 receptor (GLP-1) agonist with IC50 of 3.22 nM.
